Prevalence of Antidepressant-Associated Erectile Dysfunction

Raymond C. Rosen, Ph.D., and Humberto Marin, M.D.

Sexual dysfunction in general and erectile dysfunction in particular are common problems in the overall population but also frequent symptoms of both untreated and treated depression. Erectile dysfunction and associated sexual dysfunction secondary to antidepressant therapy may occur in up to 90% of men with antidepressant-emergent sexual side effects; accurate assessment of prevalence rates depends on taking a detailed history regarding erectile dysfunction and other aspects of sexual function prior to treatment. In this review, we examine the available data on prevalence of erectile dysfunction and related sexual dysfunction in untreated depression and secondary to antidepressant medications compared with healthy populations. Possible mechanisms involved in serotonin reuptake inhibitor (SRI)–associated erectile dysfunction are examined. The assessment of SRI-associated erectile dysfunction is presented to aid in the management of this important and prevalent side effect. Treatment of antidepressant-associated erectile dysfunction can greatly increase the likelihood that patients will continue the medication that effectively treats their depression.

From the Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway.

Support was provided by Pfizer Inc, New York, N.Y.

Dr. Rosen has been a consultant for, has received grant/research support and honoraria from, and has been on the speakers/advisory boards of Pfizer, Bayer, Palatin Technologies, Sanofi-Synthelabo, and Lilly-ICOS.

Corresponding author and reprints: Raymond C. Rosen, Ph.D., Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry, 675 Hoes Lane, Piscataway, NJ 08854-5653 (e-mail: rosen@umdnj.edu).

Antidepressant-associated erectile dysfunction can play a disruptive role in the often long-term treatment of depression. Current recommendations indicate prolonged continuation treatment for 6 to 9 months after the acute phase, as well as a long-term maintenance phase (1 year to lifetime) for patients with recurring episodes of depression. Moreover, it has been reported that approximately 25% of patients taking SRIs or other antidepressants do not complete treatment with the initially prescribed agent and switch to another. Less than half of patients taking an antidepressant fill more than 3 prescriptions, an indication that treatment is not adhered to for more than 3 months.

Treatment of antidepressant-associated sexual dysfunction should include a complete sexual history to determine the type of erectile dysfunction as well as effects on desire, arousal, orgasm, and satisfaction; potential contributing factors; and a management strategy suitable for the individual patient. Successful management can improve adherence to antidepressant therapy and potentially prevent increased morbidity and relapses.

PREVALENCE OF ERECTILE DYSFUNCTION IN HEALTHY POPULATIONS

Erectile dysfunction is a common problem in the general population and a common symptom of depression. The National Health and Social Life Survey indicated that 31% of men aged 18 to 59 years report sexual dysfunction, with 5% of those men reporting erectile dysfunction. However, erectile dysfunction is highly correlated with...
aging. The Massachusetts Male Aging Study (MMAS) reported an overall erectile dysfunction prevalence (mild, moderate, and complete) of 52% in men between the ages of 40 and 70 years; 35% of men reported moderate and complete erectile dysfunction.9 Studies in other countries support these prevalence numbers (Table 1).

**PREVALENCE OF ERECTILE DYSFUNCTION IN UNTREATED DEPRESSION**

The relationship between erectile dysfunction and depression is complex, and the causal relationship is not clear. The stress and anxiety that accompany erectile dysfunction may cause secondary depression, or erectile dysfunction can be 1 of the symptoms of major depressive disorder (MDD), or both conditions can coexist in a related or unrelated fashion.10

In a subgroup of men with MDD, a reversible loss of nocturnal penile tumescence was reported, further suggesting that depression can directly affect erectile function.10 Epidemiology studies have demonstrated an association between erectile dysfunction and depression independent of age or the presence of comorbidities.9,11,12 In the MMAS, men with depression had a 1.8 times higher chance of experiencing erectile dysfunction than those without depression, and the prevalence rates of erectile dysfunction increased as the severity of depression increased.12 In a Brazilian study of sexual behavior, a bivariate age-adjusted analysis showed a significant association between a history of depression and an increased prevalence of erectile dysfunction.13

In 2 studies of men with MDD that assessed the occurrence of sexual dysfunction prior to antidepressant therapy, 46% of men reported an inability to sustain an erection14 and 65% reported some sexual dysfunction at baseline.15 Finally, in a randomized controlled trial of 90 men with MDD, baseline prevalence of some degree of erectile dysfunction was reported at 87%. In addition, the mean number of sexual problems reported by these men was 3.6, emphasizing that in depression, single sexual complaints are rare.16

**PREVALENCE OF ERECTILE DYSFUNCTION IN TREATED DEPRESSION**

A worsening of preexisting erectile dysfunction has been reported with various agents from all antidepressant classes, including monoamine oxidase inhibitors, tricyclic antidepressants, and SRIs.1 While SRIs have transformed the treatment of depression since their release in the late 1980s and are now the most commonly prescribed antidepressants worldwide,3 sexual function disturbances associated with these agents have been prevalent. Post-marketing surveillance and clinical trials have shown the occurrence of sexual dysfunction associated with SRI use.

One surveillance study of almost 2500 patients treated with fluoxetine indicated that the incidence of sexual dysfunction was < 1.5%, an example of the inadequacy of postmarketing studies in estimating the incidence of antidepressant-associated sexual dysfunction.17 However, this type of study has the potential of distinguishing differences in the relative incidence of sexual dysfunction among different antidepressants. For example, a cohort study by the Drug Safety Research Unit of the United Kingdom comparing 4 antidepressants found that erectile dysfunction was reported significantly more often with paroxetine than with other SRIs.17 Similarly, in a comparison of the postmarketing safety profiles of antidepressants using the spontaneous adverse drug reaction reports to the United Kingdom Committee on Safety of Medicines, reports of erectile dysfunction were higher for paroxetine compared with other SRIs.17

Prerelease and early clinical studies rarely reported any SRI-associated sexual dysfunction; in fact, initially the
Table 2. Prevalence of SRI-Associated Erectile Dysfunction

<table>
<thead>
<tr>
<th>Study</th>
<th>Men, N</th>
<th>Type of Study</th>
<th>SRI Used</th>
<th>Overall Sexual Dysfunction, %</th>
<th>ED, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashton et al, 1997\textsuperscript{16}</td>
<td>167</td>
<td>Retrospective</td>
<td>Fluoxetine, Paroxetine, Sertraline, Venlafaxine</td>
<td>23.4</td>
<td>10</td>
</tr>
<tr>
<td>Jacobsen, 1992\textsuperscript{19}</td>
<td>160</td>
<td>Prospective</td>
<td>Fluoxetine</td>
<td>34</td>
<td></td>
</tr>
<tr>
<td>Montejogonzalez et al, 1997\textsuperscript{20}</td>
<td>152</td>
<td>Prospective</td>
<td>Fluoxetine</td>
<td>58 (14)a</td>
<td></td>
</tr>
<tr>
<td>Fava et al, 1998\textsuperscript{22}</td>
<td>63</td>
<td>Double-blind, placebo-controlled</td>
<td>Paroxetine, Fluoxetine</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Labbate et al, 1998\textsuperscript{21}</td>
<td>12</td>
<td>Prospective</td>
<td>Fluoxetine, Sertraline, Paroxetine</td>
<td>ND</td>
<td>58/38a</td>
</tr>
<tr>
<td>Clayton et al, 2002\textsuperscript{23}</td>
<td>183</td>
<td>Cross-sectional, observational</td>
<td>Citalopram, Venlafaxine, Sertraline, Paroxetine, Fluoxetine, Bupropion</td>
<td>Overall 7</td>
<td>ND</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Number in parentheses indicates percentage of patients reporting sexual dysfunction/ED without prompting.
\textsuperscript{b}58% and 38% of patients had decreased erection scores after 1 and 2 months of SRI therapy, respectively.

Abbreviations: ED = erectile dysfunction, ND = not determined, SRI = serotonin reuptake inhibitor.

incidence of sexual dysfunction with fluoxetine in controlled trials was reported as 1.9%,\textsuperscript{17} probably owing to the fact that no structured or validated questionnaires were used. Few studies have systematically evaluated the incidence of sexual side effects with antidepressant use (Table 2). A large-scale, nonrandomized, retrospective study of 167 men using 1 of 4 SRIs (fluoxetine, paroxetine, sertraline, or venlafaxine) for ≥ 6 months showed that 23% reported overall sexual dysfunction and 10% reported erectile dysfunction specifically.\textsuperscript{18} In a prospective study of fluoxetine in 160 outpatients, 13% of patients reported decreased sexual response.\textsuperscript{19} Similarly, in another prospective multicenter study of 152 male outpatients taking 1 of 4 SRIs, incidence of erectile dysfunction ranged from 10% (fluvoxamine) to 34% (paroxetine) depending on the SRI used.\textsuperscript{20} Labbate et al.\textsuperscript{21} reported reduced erection scores in 12 patients with MDD after 1 and 2 months of antidepressant use compared with baseline values, and Fava et al.\textsuperscript{22} demonstrated a 25% and 7% incidence of sexual dysfunction with paroxetine and fluoxetine, respectively, in a double-blind study involving 63 men. More recently, a cross-sectional, observational study conducted in > 1000 U.S. primary care clinics involving > 6000 outpatients (1763 men) receiving antidepressant therapy concluded that in a subpopulation (N = 798 [183 men]) unlikely to have predisposing factors for sexual dysfunction, the prevalence of sexual dysfunction ranged from 7% to 30%, depending on the antidepressant used.\textsuperscript{23}

PREVALENCE OF ERECTILE DYSFUNCTION SECONDARY TO OTHER SEXUAL DYSFUNCTIONS

It is well known that many antidepressants, including SRIs, cause other sexual dysfunction besides erectile dysfunction such as delayed ejaculation, anorgasmia, and decreased libido.\textsuperscript{4,17} Montejo-Gonzalez et al.\textsuperscript{20} reported in 344 patients a high incidence of loss of libido (40%–58%), delayed orgasm/ejaculation (46%–59%), or anorgasmia (31%–48%) depending on the SRI taken. These results are in agreement with other studies of patients taking antidepressants.\textsuperscript{15,16,24}

Because the link between depression and sexual dysfunction is complex, it is possible that antidepressant-associated erectile dysfunction is a consequence of other comorbid sexual dysfunction. For example, on detailed inquiry some patients have revealed that their antidepressant-induced erectile dysfunction is associated with the inability to sustain an erection long enough to achieve orgasm and ejaculation;\textsuperscript{25} thus, it could be considered that erectile dysfunction in these men occurs secondarily to prolonged ejaculatory latency.\textsuperscript{17} Similarly, because desire is the first step in the sexual response cycle and is intimately connected with sexual arousal, its absence may preclude men from engaging in sexual activity and achieving erections. Therefore, erectile dysfunction in this situation may be labeled as secondary to hypoactive sexual desire.
MECHANISMS OF ANTDRESSANT-ASSOCIATED SEXUAL AND ERECTILE DYSFUNCTION

The neurochemistry of sexual function involves multiple integrated systems. Although the precise mechanisms mediating SRI-associated sexual dysfunction are not well understood, based on evidence from case reports, uncontrolled studies, and conclusions drawn from sexual side effects observed with the use of psychotropic drugs, a number of pathways have been implicated in this process. These include serotonergic, dopaminergic, and cholinergic systems, as well as prolactin and nitric oxide.

Given the wide distribution and numerous serotonin receptor families located both centrally and peripherally, it is no surprise that serotonin mediates a number of aspects of the sexual response cycle. In general, serotonin exerts an inhibitory role on sexual function and, thus, drugs causing an increase in serotonergic activity, such as SRIs, lead to some form of sexual dysfunction. In the brain, there is evidence that serotonin causes a decrease in dopamine levels (a neurotransmitter enhancing sexual function) in animal models. Peripherally, inhibition of α-adrenergic and cholinergic receptors in the genitourinary tract also impairs sexual function; cholinergic fibers aid blood flow in the corpora cavernosa, whereas α1-receptors aid in the detumescence process. Sexual side effects have consistently been observed with SRI use but not with serotonin (5-HT1A) agonists. Apparently activation of 5-HT1A receptors may facilitate sexual behavior in rats, whereas activation of 5-HT2 receptors may be inhibitory.

Dopamine neurotransmission has been reported to play a role in sexual function (i.e., libido, psychological arousal, and erection). Agents that are potent SRI inhibitors but lack any effect on dopamine uptake inhibition, such as paroxetine, have an apparently greater incidence of sexual dysfunction than other agents with a more balanced profile. In animal models, dopamine agonists may facilitate sexual behavior in rats, whereas activation of 5-HT2 receptors may be inhibitory.

Dopamine neurotransmission has been reported to play a role in sexual function (i.e., libido, psychological arousal, and erection). Agents that are potent SRI inhibitors but lack any effect on dopamine uptake inhibition, such as paroxetine, have an apparently greater incidence of sexual dysfunction than other agents with a more balanced profile. In animal models, dopamine agonists may facilitate sexual behavior in rats, whereas activation of 5-HT2 receptors may be inhibitory.

Dopamine neurotransmission has been reported to play a role in sexual function (i.e., libido, psychological arousal, and erection). Agents that are potent SRI inhibitors but lack any effect on dopamine uptake inhibition, such as paroxetine, have an apparently greater incidence of sexual dysfunction than other agents with a more balanced profile. In animal models, dopamine agonists may facilitate sexual behavior in rats, whereas activation of 5-HT2 receptors may be inhibitory.

Dopamine neurotransmission has been reported to play a role in sexual function (i.e., libido, psychological arousal, and erection). Agents that are potent SRI inhibitors but lack any effect on dopamine uptake inhibition, such as paroxetine, have an apparently greater incidence of sexual dysfunction than other agents with a more balanced profile. In animal models, dopamine agonists may facilitate sexual behavior in rats, whereas activation of 5-HT2 receptors may be inhibitory.

Another possible explanation for the increased incidence of sexual dysfunction with SRIs is suggested by recent findings that certain SRIs are potent inhibitors of nitric oxide synthase both in vitro and in vivo; nitric oxide is a critical element in the signal transduction cascade mediating penile erection.

ASSessment of ANTDRESSANT-ASSOCIATED ERECTILE DYSFUNCTION

As recently as 20 years ago, medical school curricula did not include adequate information on how to properly elicit a sexual medical history from patients; even recent surveys among health care providers show that only 57% of physicians routinely obtain a sexual history from their patients. The incidence of antidepressant-associated erectile dysfunction is often underestimated because few patients spontaneously report their problem; in fact, many patients reported sexual difficulties only if specific questions were asked and sometimes only after repeated office visits. Similarly, it has been reported that the incidence of sexual dysfunction was 58% when physicians asked their patients about sexual function compared with a 14% incidence when self-reported by patients. Most patients clearly would like their physicians to bring up the topic of sexual health, but in many cases embarrassment by physician and patient often prevents an open discussion of sexual health, thus limiting treatment opportunity. Obtaining a complete sexual history will aid the physician in determining what type of sexual dysfunction is present; whether it is a consequence of depression, antidepressants, or other medications; and what confounding factors may play a role.

In general, it is important for physicians to recognize the fact that sexual activity is important to patients with depression and that the prevalence of erectile dysfunction in this group can be high. It is, therefore, important to evaluate the sexual function of all patients with depression and to manage the depressive disorder in a way that optimizes sexual function. As a result, patients will be less likely to discontinue antidepressant treatment and, thus, to relapse.

METHODOLOGICAL AND CONCEPTUAL CHALLENGES

During a review of the literature on the incidence of SRI-associated erectile dysfunction and other sexual...
dysfunction, a number of challenges present themselves. These include nonrandom drug assignment, use of various unstructured or nonstandardized instruments resulting in a limited assessment of sexual function, varying treatment duration, concomitant medications, and lack of equivalence in dosages, making a comparison between different antidepressants and studies difficult if not impossible.

Postmarketing surveillance studies have historically reported very low incidences of sexual dysfunction and highlight the inadequacy of such measures for obtaining realistic incidences of antidepressant-associated sexual dysfunction. Cross-sectional studies may overlook beneficial effects of SRIs on sexual response and mistakenly attribute residual dysfunction to the medication used. In clinical studies, both trial design and endpoint assessment can have major impacts on the apparent incidence of sexual side effects with SRI use. For example, none of the early clinical trials included in the product labeling of the SRIs used a structured instrument for the assessment of sexual dysfunction, and this may have contributed to the underestimate of SRI-induced sexual dysfunction with fluoxetine (1.9%). Finally, dosage of SRIs is an important point because the dose-response curve is relatively flat with respect to efficacy, whereas side effects such as sexual dysfunction are strongly dose related.

**SUMMARY**

Significant advances have been made in the treatment of depression and other related affective disorders. Although newer antidepressant treatments have fewer side effects overall, erectile dysfunction is an important, highly prevalent, and potentially distressing occurrence for patients with depression and can limit adherence to antidepressant therapy. Thus, early detection of erectile dysfunction in men with depression, with the help of a suitable questionnaire such as the Sexual Health Inventory for Men, can lead to successful management of erectile dysfunction and may increase the likelihood of antidepressant treatment continuation and minimize relapse.

**Drug names:** bupropion (Wellbutrin and others), citalopram (Celexa), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), paroxetine (Paxil), sertraline (Zoloft), venlafaxine (Effexor).

**REFERENCES**

27. Segraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275–284